Odyssey Group International Inc. ODYY Archives - Page 3 of 7

WednesdaySep 28, 2022 1:25 pm

QualityStocksNewsBreaks – Odyssey Health Inc. (ODYY) Announces Successful Completion of Phase I Clinical Trial for PRV-002

Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, today announced the completion of all cohorts for its Phase I Single Ascending Dosing (“SAD”) and Multiple Ascending Dosing (“MAD”) clinical trial. Odyssey’s trial involved administering its novel drug to treat concussion, PRV-002, to healthy human subjects. The drug was safe and well tolerated throughout the trial. “After reviewing the data from each of the cohorts, I have strong confidence that it is safe to proceed to the next clinical trial phase where PRV-002 will be administered for 10 consecutive days to subjects following concussion,” said Dallas…

WednesdaySep 28, 2022 9:00 am

Odyssey Health, Inc.’s (ODYY) Brain-Related Drug Development Programs Taking Aim at Conditions with High Unmet Clinical Needs

Odyssey is a medical company focused on products that offer clinical advantages to unmet clinical needs Its brain-related drug development programs are currently focused on treatments for concussion and the Niemann Pick Type-C (“NPC”) disease, both of which do not currently have approved treatments The company is also developing medical devices such as the intranasal drug delivery device, CardioMap, and Save-A-Life Scientists and specialists describe concussion, which is also referred to as mild traumatic brain injury (“mTBI”), as a spectrum. On the one hand, some concussed patients fully recover and do not require medical intervention or attention; on the other,…

MondaySep 26, 2022 9:45 am

Odyssey Health, Inc. (ODYY) Reports Added Evidence of Proposed Concussion Therapy’s Safety at High Doses

Medical product developer Odyssey Health Inc. is dedicated to creating solutions for a variety of life-quality situations, such as early detection of heart disease, saving choking victims and treating nervous system ailments Odyssey Health’s primary focus has been advancing its combined device and drug solution for brain concussion injuries through the clinical test process to commercial fulfillment The therapeutic solution, currently known as PRV-002, is designed to deliver a synthetic neurosteroid to injured brain tissue, where it can reduce swelling and sustain needed blood flow The company’s human testing has demonstrated safety with “no serious adverse events,” and Odyssey is…

ThursdaySep 22, 2022 2:13 pm

QualityStocksNewsBreaks – Odyssey Health Inc. (ODYY) Eyes Intranasal Brain Targeting as Key to Success of PRV-002

Odyssey Health (OTC: ODYY) announced in August the completion and findings of cohort I of the multiday ascending dosing (“MAD”) stage of its ongoing phase I clinical trial showing that PRV-002 was safe and well tolerated. A recent article reads: “Additionally, pharmacokinetic (‘PK’) analysis of the data from the first cohort provided new information that supports the hypothesis that more drug is getting to the brain itself than the circulation… The PK analysis further showed that the blood levels of the intranasally administered active drug were substantially lower on average than what would ordinarily be expected with other routes of…

ThursdaySep 15, 2022 9:00 am

Odyssey Health, Inc.’s (ODYY) PRV-002 Drug Candidate Designed to Immediately Mitigate the Effects of Concussion on Brain Function

Odyssey Health is a medical company focused on unique, life-saving medical products that offer clinical advantages to unmet clinical needs The company is currently developing a treatment for concussion, a condition that currently does not have an FDA-approved treatment despite having both short- and long-term consequences Through animal studies, Odyssey has so far evidenced that PRV-002 can easily cross the blood-brain barrier to rapidly eliminate the swelling, oxidative stress, and inflammation in the brain caused by concussion while simultaneously restoring proper blood flow Odyssey is currently undertaking Phase 1 clinical studies with plans underway to commence its Phase 2 trial…

TuesdaySep 13, 2022 12:30 pm

QualityStocksNewsBreaks – Odyssey Health Inc. (ODYY) Reports Successful Safety Outcomes for Most Recent Phase of Concussion Drug Trial

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a company focused on developing unique, life-saving medical products, has completed the safety measures for the second cohort of its phase I multiday ascending dosing (“MAD”) clinical trial. According to the announcement, the trial is designed to evaluate the company’s novel drug to treat concussion: PRV-002. During the trial, healthy human subjects received the drug in order to determine its safety; for all cohorts of the trial, PRV-002 was found to be safe and was well tolerated. The company stated that during phase 1 of the MAD trial, 16 trial participants…

MondaySep 12, 2022 11:15 am

Odyssey Health, Inc. (ODYY) Planning Phase 2 Trials of PRV-002 for Unmet Medical Needs in Concussion Therapies

Medical costs for concussions total $20 billion in the United States, a need for which there is no FDA-approved treatment The CDC estimates that more than 50% of people suffering a traumatic brain injury become moderately or severely disabled and have shorter life spans Odyssey provides a portfolio of diverse technologies and related medical products to meet the unmet medical needs of concussion and TBI patients Each year, medical costs in the United States for concussions total $20 billion ($400 billion worldwide). There is a significant unmet medical need for treatments for concussions in the medical landscape, with most diagnosed…

WednesdaySep 07, 2022 11:15 am

Odyssey Health, Inc. (ODYY) Receives Approval to Proceed with Cohort II of Its Phase I Trial’s Multiday Ascending Dosing Stage

Medical company Odyssey Health has received approval from the Safety Review Committee to start Cohort II of its Phase I trial’s Multiday Ascending Dosing (“MAD”) stage The approval follows evidence that Odyssey’s PRV-002 concussion drug candidate was safe and well-tolerated, as seen in Cohort I of the MAD stage The pharmacokinetic analysis also supports the hypothesis that more drug is getting to the brain itself, backing the company’s use of its patent-pending breath-propelled intranasal drug administration device The company believes that the intranasal drug/delivery combination will be instrumental in the success of the PRV-002 drug candidate in planned Phase II/III…

MondayAug 29, 2022 12:18 pm

QualityStocksNewsBreaks – Odyssey Health Inc. (ODYY) Featured in NeurologyLive(R) Article

Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, was featured in a recent NeurologyLive(R) article. The piece, titled “Concussion Treatment PRV-002 Demonstrates Safe, Tolerable Profile in Phase 1 Trial” and written by Marco Meglio, discusses positive results from a multiday ascending dose trial. “In cohort 1 of the multiday ascending dose (‘MAD’) trial, eight healthy human volunteers were randomly assigned 1:1 to 1 dose of PRV-003 or placebo for five consecutive days,” the article reads. “Evaluated by the Safety Review Committee, no serious adverse events were recorded, and all patients demonstrated normal vital signs, electrocardiogram…

FridayAug 26, 2022 1:09 pm

QualityStocksNewsBreaks – Odyssey Health Inc.’s (ODYY) PRV-002 Poised to Offer First-of-Its-Kind Responsiveness to Concussion

Odyssey Health (OTC: ODYY), a medical device innovator and biopharmaceutical product developer, has been advancing a proposed solution for brain injury from concussive forces. “Odyssey Health’s novel compound PRV-002 is the combination of a device and the medicine it delivers to treat concussions during the first moments after their occurrence, before permanent or long-term damage can set in. No U.S. Food and Drug Administration (‘FDA’)-approved drug treatment exists for concussion, and medical providers are generally left to rely on prescribed rest to help patients recover. But if Odyssey’s product can be established as safe and effective, it will open doors…

Site Search

Company Search

Tag: Odyssey Group International Inc. ODYY